A San Diego upstart armed with FDA clearance, first commercial shipments, and an audacious two-part pump design is stepping into a multi-billion-dollar market that the industry’s giants have repeatedly fumbled
The Patient Nobody Wanted to Build For
For decades, the diabetes device industry chased the same customer: the highly motivated, technically sophisticated Type 1 diabetic willing to master a gadget that resembles something NASA might bolt onto a satellite. The result was a generation of insulin pumps that were clinically brilliant and practically intimidating — bulky, tubed, expensive, and perpetually beeping at inopportune moments, like graduation ceremonies and first dates.
Meanwhile, approximately 70% of insulin-dependent adults remained on multiple daily injections (MDI) — not because pumps don’t work, but because existing pumps were too complex, too cumbersome, and too costly for the average patient to justify the switch. This underserved population — what the industry calls “almost-pumpers” — represents an estimated $3 billion addressable market that incumbents like Medtronic (NYSE: MDT), Insulet Corporation (NASDAQ: PODD), and Tandem Diabetes Care (NASDAQ: TNDM) have largely left untouched.
Modular Medical, Inc. (NASDAQ: MODD), a San Diego-based medical device company founded by Paul DiPerna — the same engineer who invented Tandem’s original t:slim pump — has spent several years engineering a different kind of answer. Now, with FDA clearance secured and first commercial shipments underway, the company is making its opening move into that market gap.
The Pivot: Engineering Simplicity as a Strategy
The Pivot™ tubeless insulin patch pump is not a minor product iteration — it is a structural rethinking of how an insulin pump should be designed. Unlike conventional systems that require constant wear, battery recharging, and a tangle of infusion tubing, the Pivot features a two-part architecture: a reusable controller and a disposable 3 mL reservoir, all without a single tube connecting anything to anything.
Key design features include smartphone connectivity for bolus dosing and monitoring, a quick-action bolus button that bypasses the need for a separate controller in routine use, true electronic dosing accuracy, and the ability to remove the device entirely for showers, sports, or those moments when discretion matters more than glycemic precision. The battery is disposable — no charging cables, no nightly docking ritual, no forgotten chargers in airport security bins.
The company’s initial manufacturing capacity supports approximately 6,000 users, anchored by a scalable, low-cost platform designed to ramp production aggressively as adoption grows. Software enhancements already in the development pipeline include variable bolus delivery, improved alarms, and compatibility with Automated Insulin Delivery (AID) closed-loop systems — the frontier of diabetes technology that is rapidly becoming the standard of care.
From Clinician Feedback to Commercial Reality
The path to the Pivot’s commercial launch was methodical, if not always smooth. In September 2025, Modular Medical completed a clinical study of its predecessor device, the MODD1 pump, deploying it on nine clinicians with Type 1 diabetes who already wore continuous glucose monitors (CGMs) and other pump systems. The study was designed specifically to stress-test ease of use for converting multiple-daily-injectors to pump therapy — exactly the patient population the company intends to pursue.
CEO Jeb Besser described the exercise in characteristically understated corporate prose: the company thanked the clinicians for their time, noted learnings, and promised improvements. What the exercise actually demonstrated was that a medical device company was doing something rare — asking real users with real clinical opinions to break the product before patients had to.
From there, Modular Medical moved with disciplined speed. The company received Institutional Review Board (IRB) approval to conduct a Pivot feasibility study using sterile saline in real-world conditions. The Pivot controller manufacturing line was validated for human-use production in November 2025. FDA 510(k) clearance arrived in April 2026, formally unlocking U.S. commercial sales. And on June 24, 2026, Modular Medical announced that the Pivot was commercially available — with first shipments of starter kits dispatched to select high-volume endocrinology practices just days later.
The Market: Big Numbers, Bigger Opportunity
The tailwind behind Modular Medical’s launch is not subtle. The global insulin pump market was valued at approximately $7.05 billion in 2025 and is projected to grow to $8.20 billion in 2026, with estimates ranging as high as $22.45 billion by 2034 depending on the methodology applied. A separate analysis pegs the market at $6.6 billion in 2025, expanding at a compound annual growth rate of 12.7% through 2035.
Insulet Corporation (NASDAQ: PODD) — the maker of the Omnipod, the market’s dominant tubeless patch pump — reported total annual revenue of $2.7 billion for fiscal year 2025, driven in large part by its Omnipod 5 AID system and aggressive expansion into the Type 2 diabetes market. By the end of 2025, Type 2 users represented more than 40% of all new U.S. Insulet customer starts — validation that the “almost-pumper” population is not only real, but commercially pursable.
What Modular Medical is betting on is a price-point and simplicity gap that Insulet, with its premium positioning, has not filled. Pivot’s two-part reusable architecture is designed to bring total cost of ownership materially below competing systems, directly addressing the affordability barrier that keeps the majority of insulin-dependent adults on injections.
Nasdaq Compliance: The Chapter They’d Rather Not Dwell On
No investor-focused account of Modular Medical would be complete without acknowledging the period during which the company’s stock spent considerable time at addresses the Nasdaq would politely describe as “below minimum standards.” Following a steep decline, MODD received a 180-day extension from Nasdaq in December 2025 to regain compliance with the exchange’s minimum $1.00 bid price requirement.
The company executed a 1-for-30 reverse stock split in late March 2026, a maneuver that — while not the sort of corporate action that generates investor enthusiasm — did the technical job it was designed to do. By April 14, 2026, MODD’s stock had maintained a closing bid above $1.00 for 10 consecutive trading days, and Nasdaq formally confirmed compliance restored under Rule 5550(a)(2).
The episode is a reminder that Modular Medical is an early-stage company with the financial profile that entails: zero revenue in fiscal year 2026, a widening net loss, and explicit going-concern language in its most recent 10-K filing. Investors considering MODD are pricing a speculative bet on execution — on whether a well-designed product with a genuinely differentiated market thesis can achieve the commercial traction necessary to survive and scale.
The Commercialization Roadmap: Phases, Not Promises
Modular Medical is not promising to conquer the insulin pump market by Christmas. Its commercial expansion is structured in deliberate phases — an approach that reflects either admirable capital discipline or the reality that a company with limited resources has no viable alternative. Either way, the logic is sound.
The initial phase, now underway, targets select high-volume endocrinology practices where physicians already manage large populations of insulin-dependent adults. Pivot starter kits are shipping, physician training is being completed, and the company expects to update the market when the first patients begin using the pump for actual insulin delivery. A broader rollout across multiple metropolitan markets is expected by late 2026. European CE Mark approval is targeted for Q4 2026 or Q1 2027, which would open the company’s first international revenue channel.
Software enhancements that would qualify the Pivot for AID (automated, closed-loop insulin delivery) compatibility represent the medium-term product roadmap — a capability that, if achieved, would move the company from the affordability tier into genuine clinical competition with the market’s leading systems. For context, Insulet’s Omnipod 5 and Tandem’s Control IQ are currently the leading AID systems in the U.S. market; Medtronic (NYSE: MDT), meanwhile, is navigating a significant corporate restructuring that may temporarily reduce its competitive agility.
The Founder’s Blueprint
Paul DiPerna, who founded Modular Medical after previously founding Tandem Diabetes Care (NASDAQ: TNDM) and inventing its original t:slim pump, understood from experience precisely what made existing insulin delivery systems unnecessarily complicated. That institutional knowledge — of where complexity enters the manufacturing process, where the patient experience degrades, where cost accumulates without clinical payoff — is embedded in the Pivot’s design philosophy.
The company’s stated mission is to bring “diabetes care for the rest of us” — glycemic control not just for the highly motivated superusers who currently dominate pump adoption, but for the broader population of insulin-dependent adults who would benefit from pump therapy and have been, until now, underserved by the industry’s default assumptions about what patients can and will manage.
Risks Worth Naming Plainly
Sophisticated investors know that a compelling narrative and a commercially viable business are not the same thing. Modular Medical’s fiscal year 2026 10-K disclosed zero revenue, a net loss of $28.2 million, and going-concern risk. The company has required repeated capital raises to fund operations, including a $12 million public offering in March 2026.
The competitive landscape is imposing. Insulet (NASDAQ: PODD) operates at 40+ times Modular Medical’s scale, with manufacturing facilities optimized for high-volume output, a pharmacy-channel distribution moat, and a software platform that has already achieved AID regulatory clearance. Tandem Diabetes Care (NASDAQ: TNDM) is developing its own next-generation patch pump. Medtronic (NYSE: MDT) remains the dominant global player by installed base despite competitive pressure.
What Modular Medical offers — should its commercial execution prove credible — is exposure to a genuinely underserved market segment at a pre-revenue valuation. Whether that valuation reflects an opportunity or simply the risk profile of an undercapitalized early-stage device company is a question each investor must answer for themselves. What is no longer in question is that the Pivot exists, has FDA clearance, and is shipping to physicians. The company has cleared the hardest regulatory hurdle. The commercial hurdle now begins.
Modular Medical, Inc. trades on the Nasdaq Capital Market under the ticker symbol MODD. All forward-looking statements are subject to material risks as described in the company’s SEC filings. This article is for informational purposes only and does not constitute investment advice.
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
